Skip to main content
. 2023 Jan 10;29(11):1730–1740. doi: 10.1093/ibd/izac269

Figure 1.

Figure 1.

Kaplan-Meier curve showing the cumulative rates of vedolizumab (VDZ) treatment persistence (A) in patients with ulcerative colitis (UC) and Crohn’s disease (CD), (B) biologic-naïve and biologic-exposed patients with UC, and (C) biologic-naïve and biologic-exposed patients with CD at 3, 6, 9, and 12 months.